MedinCell S.A.

MEDCL

FR0004065605

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 11:35:06 2025-01-17 am EST			5-day change	1st Jan Change
16.30 ^EUR	+0.37%		-1.09%	-1.93%

Dec. 13	Eutelsat: delisted from the SBF 120 and CAC Mid 60 indices	CF
Dec. 13	Euroapi: delisted from the SBF 120 and CAC Mid 60 indices	CF

MedinCell S.A. Reports Earnings Results for the Full Year Ended March 31, 2024

June 10, 2024 at 02:00 am EDT

MedinCell S.A. reported earnings results for the full year ended March 31, 2024. For the full year, the company reported sales was EUR 9.03 million compared to EUR 9.89 million a year ago. Revenue was EUR 11.95 million compared to EUR 13.66 million a year ago.

Net loss was EUR 25.04 million compared to EUR 32.01 million a year ago.

Latest news about MedinCell S.A.

Eutelsat: delisted from the SBF 120 and CAC Mid 60 indices	Dec. 13	CF
Euroapi: delisted from the SBF 120 and CAC Mid 60 indices	Dec. 13	CF
Casino: delisted from the SBF 120 and CAC Mid 60 indices	Dec. 13	CF
Casino exits SBF 120, Medincell, Planisware and Robertet included	Dec. 13	RE
Medincell joins the SBF 120 and CAC Mid 60 indexes	Dec. 13	CF
MedinCell S.A. Provides Earning Guidance for the Year Ending March 31, 2025	Dec. 10	CI
MedinCell S.A., H1 2025 Earnings Call, Dec 10, 2024	Dec. 10
MedinCell S.A. Reports Earnings Results for the Half Year Ended September 30, 2024	Dec. 09	CI
Medincell: positive results in arthroplasty	Dec. 09	CF
Medincell: in the green with study data	Nov. 04	CF
MedinCell: Mirova exceeds 5% of voting rights	24-10-01	CF
MedinCell S.A.(ENXTPA:MEDCL) added to S&P Global BMI Index	24-09-22	CI
MedinCell S.A. Confirms Stéphane Postic as CFO	24-09-13	CI
MedinCell S.A. Appoints Christophe Douat as Chief Executive Officer	24-09-13	CI
MedinCell S.A. Announces Board Appointments	24-09-13	CI
Such a long wait	24-09-05
Medincell: program with AbbVie enters pre-clinical phase	24-09-04	CF
Medincell Announces Progress in the Development of Its Products Portfolio and R&D Pipeline	24-09-03	CI
MedinCell: Mirova exceeds 5% of voting rights	24-08-29	CF
Medincell: R&D advances soon to be presented at congress	24-07-02	CF
MedinCell S.A., 2024 Earnings Call, Jun 10, 2024	24-06-10
Medincell: a 'new era' after a 'pivotal' 2023	24-06-10	CF
MedinCell S.A. Reports Earnings Results for the Full Year Ended March 31, 2024	24-06-10	CI
Medincell: share price falls after disappointing clinical study	24-05-15	CF
MedinCell S.A. - Special Call	24-05-15

Chart MedinCell S.A.

Duration

Period

MEDCL: Dynamic Chart

Company Profile

MedinCell S.A. is a pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas, combining its proprietary BEPO® technology with active ingredients already known and marketed. The BEPO® technology allows the regular delivery of a drug at optimal therapeutic dose for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, fully bioresorbable. The first treatment based on BEPO® technology, intended for the treatment of schizophrenia, was approved by the FDA in April 2023, and is now distributed in the United States by Teva under the name UZEDY® (BEPO® technology is licensed to Teva under the name SteadyTeqTM). As of March 31, 2024, the company had a portfolio of 2 products in phase III clinical development and 2 products in preclinical development.

Employees

131

Sector

Pharmaceuticals

Calendar

2025-06-16 - Q4 2025 Earnings Release

More about the company